Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.43 |
| ▸ | LPL | P06858 | 12/20 | 0.43 |
| ▸ | F11 | P03951 | 2/20 | 0.37 |
| ▸ | P4HB | P07237 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.35 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19652465 | 1.00 | LIPG (0.43) | LIPGLPLF11P4HBCA1 | |
| SCHEMBL17903421 | 1.00 | LIPG (0.43) | LIPGLPLF11P4HBCA1 | |
| SCHEMBL17903435 | 0.87 | LIPG (0.44) | LIPGLPLF11P4HBCA1 | |
| SCHEMBL1129175 | 0.85 | LIPG (0.59) | LIPGLPLF11P4HBCA1 | |
| SCHEMBL17903440 | 0.85 | LIPG (0.42) | LIPGLPLF11P4HBCA1 | |
| SCHEMBL17893865 | 0.85 | LIPG (0.42) | LIPGLPLF11P4HBCA1 | |
| SCHEMBL1129310 | 0.85 | LIPG (0.48) | LIPGLPLF11P4HBCA1 | |
| SCHEMBL17903578 | 0.85 | LIPG (0.42) | LIPGLPLF11P4HBCA1 | |
| SCHEMBL17894262 | 0.85 | LIPG (0.42) | LIPGLPLF11P4HBCA1 | |
| SCHEMBL17894260 | 0.85 | LIPG (0.42) | LIPGLPLF11P4HBCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180118766-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20170342076-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118766-A1 | BTK INHIBITORS | BTK, SYK, LYN | LIPG 1114/4885LPL 2228/4885F11 1015/4885 |
| US-20170342076-A1 | TERTIARY ALCOHOL IMIDAZOPYRAZINE BTK INHIBITORS | BTK, SYK, ABL1 | LIPG 1648/4885LPL 2325/4885F11 775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.